Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BMI1 proto-oncogene, polycomb ring finger pseudogene 1 (BMI1P1) is a **pseudogene** of the BMI1 proto-oncogene. BMI1P1 does not code for a functional protein, but may be transcribed as a long non-coding RNA (lncRNA), sometimes called lnc-OPHN1-5. As a pseudogene, BMI1P1 itself is not considered a classic drug target such as a receptor, enzyme, or transporter. Its only role may be indirect regulation of gene expression by serving as a decoy or sponge in competitive endogenous RNA (ceRNA) networks, possibly affecting the expression of its functional parent gene, BMI1, which has well-established oncogenic functions. However, there is no evidence that BMI1P1 is a validated therapeutic target or biomarker, and its molecular and functional biology is poorly characterized compared to BMI1[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BMI1 proto-oncogene, polycomb ring finger pseudogene 1 (BMI1P1).